Abstract:The study aimed to develop a technology for the production of a finished form of medicinal probiotic agents against human intestinal infections based on active strains of lactic acid and propionic acid bacteria with a wide range of biological activity and resistance to antibiotics. From the laboratory collection of lactic acid and propionic acid bacteria isolated from the intestines of healthy people, two associations of bacteria were compiled with antagonism against test cultures of Staphylococcus aureus, Salmonella gallinarum, Mycobacterium B5, Candida albicans, Pasteurella multocida, Bacillus subtilis, Escherichia coli 8739, Klebsiella pneumoniae ATCC 700603 and ATCC BAA 2524, Staphylococcus aureus 3316 and 9, Salmonella enteritidis 35382, and Pseudomonas aeruginosa 835, as well as the ability to produce hydrolytic enzymes amylase and proteinase, B vitamins, and essential amino acids. The resistance of the selected associations of lactic acid and propionic acid bacteria to the used antibiotics has been studied, which will allow for using them, if necessary, in the complex therapy of diseases. Technology for the production of probiotic medication from these associations has been developed. It was found that the most active preparation in terms of bacterial titer and antagonistic activity and the most stable one during storage for 6 months was the liquid preparation obtained by growing association No. 2 (L. plantarum 2v/A-6+L. brevis B-3/A-26+L. acidophilus 27w/60+P. shermanii 8) on nutrient medium No. 1 (De Man, Rogosa and Sharpe agar with CoCl2) using 7% sucrose and 1.5% gelatin as a protector. The liquid preparation from association No. 5 grown on medium No. 1 showed a more complete preservation of production-valuable signs during storage compared to the results of using nutrient medium No. 4, while the use of protector No. 1 was more optimal. To test the stability during the storage of dry preparation forms, an accelerated method was used by warming them up for 15 minutes at 60°C. It was found that after warming up, the best preservation of viable bacterial cells was observed in association No. 2 on nutrient media No. 1 and No. 4, in association No. 5 on medium No. 4 dried with protector No. 2 (7% sucrose and 1.5% gelatin + 7% skim milk powder), while the titer of bacteria was equal to 1.2×109, 3.5×108, and 2.0±0.2×108 colony-forming units/g, respectively. Antagonistic activity in these association variants was observed against all test cultures taken into the study with zones of suppression of their growth ranging from 10 to 24 mm.

Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)

Survival of Probiotic Bacterial Cells in the Upper Gastrointestinal Tract and the Effect of the Surviving Population on the Colonic Microbial Community Activity and Composition

Targeted delivery of probiotics to enhance gastrointestinal stability and intestinal colonisation

In Vitro Development of Enteric-Coated Tablets of the Probiotic Lactobacillus fermentum LF-G89: A Possible Approach to Intestinal Colonization.

Effect of Simulated Gastrointestinal Tract Conditions on Survivability of Probiotic Bacteria Present in Commercial Preparations

Carboxymethyl Konjac Glucomannan-Chitosan Complex Nanogels Stabilized Emulsions Incorporated into Alginate As Microcapsule Matrix for Intestinal-Targeted Delivery of Probiotics: in Vivo and in Vitro Studies.

Surviving process and transit: Controlled freeze drying, storage and enteric coated capsules for targeted delivery of probiotic Lactobacillusacidophilus

Microencapsulation of new probiotic formulations for gastrointestinal delivery: in vitro study to assess viability and biological properties

Simulating colonic survival of probiotics in single-strain products compared to multi-strain products

Effect of Cell Concentration on the Persistence in the Human Intestine of Four Probiotic Strains Administered through a Multispecies Formulation

Use of Artificial Digestive Systems to Investigate the Biopharmaceutical Factors Influencing the Survival of Probiotic Yeast During Gastrointestinal Transit in Humans

An in vitro gastrointestinal model to evaluate the tolerance of encapsulated Lactobacillus and Lactococcus strains with synbiotic containing lactobionic acid via lyophilization technique to harsh gastric conditions during storage time

Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract

Probiotic Encapsulation: Bead Design Improves Bacterial Performance during In Vitro Digestion

Development of Technology for the production of finished forms of Medicinal probiotics

Development of a novel probiotic delivery system based on microencapsulation with protectants

Survival and Release Behavior of a Novel Pre-, Pro-, and Postbiotic Capsule in an In Vitro SHIME Model

Probiotic goat milk tablets: Formulation optimization and stability evaluation

Storage stability and <i>in vitro</i> digestion of microencapsulated powder containing fermented noni juice and probiotics

Safety and persistence of orally administered human Lactobacillus sp. strains in healthy adults

The viability of complex coacervate encapsulated probiotics during simulated sequential gastrointestinal digestion affected by wall materials and drying methods